Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
Belgium's Loi du 29 février 2024 (published in the Moniteur Belge on 27 May 2024, entering into force 1 June 2026) establishes the first comprehensive federal authorisation and traceability regime for pharmaceutical raw materials used by pharmacists in extemporaneous and magistral preparations. Manufacturers, importers, and distributors of covered materials must obtain AFMPS authorisation and comply with Good Manufacturing Practice and Good Distribution Practice standards; pharmacists may only source materials from authorised actors. The statute was enacted during Belgium's EU Council Presidency (H1 2024) and directly parallels the EU Critical Medicines Alliance architecture launched in Leuven on 24 April 2024, positioning Belgium as the first EU member state to operationalise a national supply-chain control layer for pharmaceutical compounding raw materials ahead of the forthcoming EU Critical Medicines Act.
The Bureau of Industry and Security (BIS) amended the Chemical Weapons Convention Regulations (CWCR, 15 CFR Part 710) and Export Administration Regulations (EAR, 15 CFR Parts 712 and 745) to implement two OPCW Conference of States Parties decisions (C-24/DEC.4 and C-24/DEC.5) from November 2019. The rule adds four chemical families — two families of alkyl phosphonamidic fluorides, O-alkyl phosphoramidofluoridates, and quaternary/bisquaternary carbamates — to CWC Schedule 1(A), effective immediately upon publication. The rule also clarifies the definition of "production" in 15 CFR § 710.1 to include intermediates, by-products, and waste products generated within a defined manufacturing sequence.